Program
apazunersen sodium
Also written as “GTX-102”, “GTX-102 medium dose fast Period 1 and Period 2” and “GTX-102 medium dose slow Period 1 and Period 2”.
Its studies are mostly in Angelman Syndrome · Ataxia Telangiectasia, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ultragenyx Pharmaceutical | 40 open or running | phase 3since May 10, 2024 | Jan 31, 2020 | none ahead |
| Grace Therapeutics | 10 open or running | phase 1since Aug 31, 2022 | Aug 31, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 31, 2020First study: phase 2 study in Angelman SyndromeNew to Ultragenyx PharmaceuticalUltragenyx Pharmaceutical · NCT04259281 · 74 enrolled · United States, Australia, Canada and more
- Aug 31, 2022Grace Therapeutics's first study: phase 1 study in Ataxia TelangiectasiaNew to Grace TherapeuticsGrace Therapeutics · NCT05531890 · 48 enrolled · Canada
- May 10, 2024Phase 3 study in Angelman SyndromeUltragenyx Pharmaceutical · NCT06415344 · 66 enrolled · United States, Australia, Canada and more
- Sep 24, 2024Phase 3 study in Angelman SyndromeUltragenyx Pharmaceutical · NCT06617429 · 129 enrolled · United States, Canada, Germany and more
- Aug 21, 2025Phase 2 study in Angelman SyndromeUltragenyx Pharmaceutical · NCT07157254 · 55 enrolled · United States, Argentina, Brazil and more
- Nov 3, 2026Phase 3 study terminatedStudy stoppedNCT06415344 · “Lack of efficacy”
- Nov 3, 2026Phase 3 study terminatedStudy stoppedNCT06617429 · “Lack of efficacy”
- Nov 3, 2026Phase 2 study terminatedStudy stoppedNCT07157254 · “Lack of efficacy”
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07157254Angelman Syndrome · United States, Argentina, Brazil and more | 2 | Terminated | Ultragenyx Pharmaceutical | Oct 30, 2026 | 55 |
| NCT06617429Angelman Syndrome · United States, Canada, Germany and more | 3 | Terminated | Ultragenyx Pharmaceutical | Jul 10, 2026 | 129 |
| NCT06415344Angelman Syndrome · United States, Australia, Canada and more | 3 | Terminated | Ultragenyx Pharmaceutical | Oct 30, 2026 | 66 |
| NCT05531890Ataxia Telangiectasia · Canada | 1 | UNKNOWN | Grace Therapeutics | Nov 24, 2022 | 48 |
| NCT04259281Angelman Syndrome · United States, Australia, Canada and more | 2 | Completed | Ultragenyx Pharmaceutical | Jan 8, 2025 | 74 |
How it is read
Names in the registry
- “GTX-102”, 4 entries
- “GTX-102 medium dose fast Period 1 and Period 2”, 1 entry
- “GTX-102 medium dose slow Period 1 and Period 2”, 1 entry
- “GTX-102 high dose fast Period 1 and Period 2”, 1 entry
- “GTX-102 low dose fast Period 1 and Period 2”, 1 entry
Codes read as this program: GTX102.
Conditions, from the studies’ own filings
- Angelman Syndrome, 4 studies
- Ataxia Telangiectasia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.